52.17

0.56% 0.29

Moonlake Immunotherapeutics (MLTX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt MLTX? Forum Prognose

Schlusskurs vom Vortag:

$51.88

Offen:

$51.71

24-Stunden-Volumen:

190.98K

Relative Volume:

0.68

Marktkapitalisierung:

$3.29B

Einnahmen:

Nettoeinkommen (Verlust:

$-80.77M

KGV:

-44.62

EPS:

-1.1692

Netto-Cashflow:

$-80.80M

1W Leistung:

+1.62%

1M Leistung:

+4.72%

6M Leistung:

+32.11%

1J Leistung:

-9.32%

1-Tages-Spanne:

$50.21

$54.10

1-Wochen-Bereich:

$50.21

$58.26

52-Wochen-Spanne:

$37.55

$64.98

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Firmenname

Moonlake Immunotherapeutics

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

41 41 510 8022

Adresse

DORFSTRASSE 29, ZUG

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

MLTX's Discussions on Twitter

Vergleichen Sie MLTX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MLTX Moonlake Immunotherapeutics	52.17	3.29B	0	-80.77M	-80.80M	-1.27
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-11-05	Fortgesetzt	Wedbush	Outperform
2024-08-26	Herabstufung	Wolfe Research	Outperform → Peer Perform
2024-06-25	Eingeleitet	Oppenheimer	Outperform
2024-04-02	Eingeleitet	Goldman	Neutral
2024-02-15	Eingeleitet	Wolfe Research	Outperform
2023-12-08	Eingeleitet	Citigroup	Buy
2023-11-02	Eingeleitet	Stifel	Buy
2023-09-14	Herabstufung	Bryan Garnier	Buy → Neutral
2023-08-31	Eingeleitet	Needham	Buy
2023-06-15	Eingeleitet	Barclays	Equal Weight
2023-05-01	Eingeleitet	Guggenheim	Buy
2023-03-22	Eingeleitet	Wedbush	Outperform
2023-03-09	Eingeleitet	BTIG Research	Buy
2023-02-14	Eingeleitet	Cantor Fitzgerald	Overweight
2023-02-02	Eingeleitet	Bryan Garnier	Buy
2022-11-11	Eingeleitet	Jefferies	Buy
2022-08-25	Eingeleitet	SVB Leerink	Outperform
2022-07-21	Eingeleitet	H.C. Wainwright	Buy
2022-07-07	Eingeleitet	Cowen	Outperform

Alle ansehen

Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten

Dec 20, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Down 3.2%What's Next? - MarketBeat

Dec 20, 2024

Dec 18, 2024

MoonLake Immunotherapeutics announces board change, incentive plan - Investing.com

Dec 18, 2024

MoonLake Immunotherapeutics Announces Board Changes and Incentives - TipRanks

Dec 18, 2024

MoonLake Immunotherapeutics announces board change, incentive plan By Investing.com - Investing.com UK

Dec 18, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 18, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Dec 18, 2024

Dec 17, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 7.9%Here's What Happened - MarketBeat

Dec 17, 2024

Dec 16, 2024

We're Not Very Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Rate - Simply Wall St

Dec 16, 2024

Wellington Management Group LLP Cuts Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Dec 16, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Dec 16, 2024

Dec 15, 2024

Trading (MLTX) With Integrated Risk Controls - Stock Traders Daily

Dec 15, 2024

Dec 14, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.6%What's Next? - MarketBeat

Dec 14, 2024

Dec 13, 2024

MoonLake Immunotherapeutics' SWOT analysis: stock outlook amid HS market potential - Investing.com

Dec 13, 2024

Dec 12, 2024

Clear Street sets $108 target on Moonlake Immunotherapeutics stock By Investing.com - Investing.com UK

Dec 12, 2024

Clear Street sets $108 target on Moonlake Immunotherapeutics stock - Investing.com

Dec 12, 2024

Dec 10, 2024

MoonLake Immunotherapeutics Reports Q3 2024 Financial Results - MSN

Dec 10, 2024

Dec 06, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by The Manufacturers Life Insurance Company - Defense World

Dec 06, 2024

Dec 05, 2024

When (MLTX) Moves Investors should Listen - Stock Traders Daily

Dec 05, 2024

Dec 04, 2024

Erste Asset Management GmbH Invests $741,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Dec 04, 2024

Dec 02, 2024

Fmr LLC Purchases 1,306,215 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Dec 02, 2024

Nov 25, 2024

Westfield Capital Management Co. LP Boosts Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Nov 25, 2024

Nov 24, 2024

(MLTX) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 24, 2024

Nov 23, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $79.00 Consensus PT from Brokerages - MarketBeat

Nov 23, 2024

Nov 21, 2024

MoonLake Immunotherapeutics: A Somewhat Complicated Story (NASDAQ:MLTX) - Seeking Alpha

Nov 21, 2024

Victory Capital Management Inc. Has $10.98 Million Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Nov 21, 2024

Nov 19, 2024

MoonLake Immunotherapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 19, 2024

Nov 18, 2024

MoonLake Immunotherapeutics management to meet with Oppenheimer - TipRanks

Nov 18, 2024

Nov 14, 2024